9+ hour, 41+ min ago  (565+ words) Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMo D from the Company's targeted protein degradation platform, in relapsed or refractory multiple myeloma Additional data from the Company's differentiated pipeline including pumitamig, iza-bren, iberdomide and golcadomide to…...